Vistagen Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
3.2%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$1.48next fiscal year
Monitoring Framework
Key Performance Indicators
PALISADE-4 Phase 3 Topline Efficacy (SUDS Score) QuarterlyTarget: Statistically significant reduction in Subjective Units of Distress Scale (SUDS) vs placebo
Cash Runway (Months of Funding) QuarterlySufficient cash into 2027Target: Sufficient cash to fund operations into 2027
Fasedienol Safety Exposure (ICH E1 Compliance) Annually1.5KTarget: Maintain minimum patient exposure levels (>300 for 6 months, >100 for 12 months) to support NDA
Watch Items
- PALISADE-4 Phase 3 Topline Data ReadoutTrigger: Topline results release expected in June 2026Action: Evaluate primary endpoint statistical significance and prepare for potential NDA submission if successful
- Phase 2 Repeat Dose Study of FasedienolTrigger: Topline results expected in Q3 2026Action: Assess safety and efficacy of repeat dosing to support long-term clinical utility and regulatory filings
- Refisolone (PH80) Phase 2 Clinical DevelopmentTrigger: Initiation of U.S. Phase 2 trials following FDA 'Study May Proceed' clearanceAction: Monitor patient enrollment and initial safety/efficacy signals in menopausal hot flashes
Research as of 20 Jun 2026